Outcome of patients with sarcoma and other mesenchymal tumors participating in phase I trials: a subset analysis of a European Phase I database
Cassier, P A × Polivka, V Judson, I Soria, J-C Penel, N Marsoni, S Verweij, J Schellens, J H Morales-Barrera, R Schöffski, Patrick Voest, E E Gomez-Roca, C Evans, T R J Plummer, R Gallerani, E Kaye, S B Olmos, D #
Kluwer Academic Publishers
Annals of Oncology vol:25 issue:6 pages:1222-8
Although sarcomas account for only 1% of all solid tumors, patients with sarcomas comprise a larger proportion of patients entering phase I trials, due to the limited number of registered or active drugs for these diseases. To help in patient selection, we evaluated the utility of the predictive Royal Marsden Score which had been derived in carcinoma patients. In addition we analysed efficacy and toxicity regarding the sarcoma population enrolled in phase I trials.